CStone Pharmaceuticals (HK:2616) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
CStone Pharmaceuticals has unveiled promising preclinical data for its innovative trispecific antibody, CS2009, at the SITC Annual Meeting. Designed to target PD-1, CTLA-4, and VEGFA, CS2009 shows superior anti-tumor activity and potential applicability across various cancer types. The company anticipates initiating first-in-human trials by early 2025, marking a significant step forward in cancer immunotherapy.
For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.